Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Jazz Pharmaceuticals plc

SG&A Trends: Insmed's Rapid Growth vs. Jazz's Steady Lead

__timestampInsmed IncorporatedJazz Pharmaceuticals plc
Wednesday, January 1, 201431073000406114000
Thursday, January 1, 201543216000449119000
Friday, January 1, 201650679000502892000
Sunday, January 1, 201779171000544156000
Monday, January 1, 2018168218000683530000
Tuesday, January 1, 2019210796000736942000
Wednesday, January 1, 2020203613000854233000
Friday, January 1, 20212342730001451683000
Saturday, January 1, 20222657840001416967000
Sunday, January 1, 20233445010001343105000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of SG&A: Insmed vs. Jazz Pharmaceuticals

In the competitive landscape of pharmaceuticals, operational efficiency is key. Over the past decade, Insmed Incorporated and Jazz Pharmaceuticals plc have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion strategy. In contrast, Jazz Pharmaceuticals, while maintaining a higher baseline, saw a more modest increase of around 230% during the same period.

Key Insights

  • 2014-2018: Insmed's expenses grew steadily, while Jazz maintained a consistent lead, spending nearly 10 times more than Insmed in 2014.
  • 2019-2023: Insmed's expenses accelerated, closing the gap with Jazz, whose expenses peaked in 2021.

This analysis highlights the strategic choices of these companies, with Insmed focusing on rapid growth and Jazz on sustaining its market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025